Webinars

All webinars listed below are available OnDemand.

Webinar #1: Novel Discoveries in Endometrial Cancer:
Are we finally making progress?

Moderators/Distillants: Melissa A. Geller, MD, and Shannon N. Westin, MD, MPH

  • A randomized phase II/III study of paclitaxel/carboplatin/metformin versus paclitaxel/carboplatin/placebo as initial therapy for measurable stage III or IVA, stage IVB, or recurrent endometrial cancer: An NRG oncology/GOG study – V. Bae-Jump
  • Randomized phase II trial of carboplatin-paclitaxel compared to carboplatin-paclitaxel-trastuzumab in advanced or recurrent uterine serous carcinomas that overexpress Her2/neu (NCT01367002): Updated survival analysis – A. N. Fader
  • Safety and efficacy of the anti–PD-1 monoclonal antibody dostarlimab in patients with recurrent or advanced dMMR endometrial cancer – R. Sabatier
  • Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: Final analysis of a multicentre, open-label, single-arm, phase 2 trial – V. Makker
  • A phase II trial of the Wee1 inhibitor adavosertib (AZD1775) in recurrent uterine serous carcinoma – J. F. Liu

View Abstracts

 Registration Link For OnDemand Webinar (SGO ConnectEd)

Webinar #2: Paradigm Changes in Front Line Ovarian Cancer

Moderators/Distillants: Thomas J. Herzog, MD, and Kathleen N. Moore, MD

  • Efficacy of niraparib therapy in patients with newly diagnosed advanced ovarian cancer by BRCA and homologous recombination status: PRIMA/ENGOT-OV26/GOG-3012 study – B. J. Monk
  • Time to first subsequent therapy (TFST) and progression-free survival 2 (PFS2) from the phase 3 randomized, double-blind PRIMA/ENGOT-OV26/GOG-3012 study in patients with newly diagnosed ovarian cancer – S. N. Han
  • Phase III PAOLA-1/ENGOT-ov25: maintenance olaparib with bevacizumab in patients with newly diagnosed, advanced ovarian cancer treated with platinum-based chemotherapy and bevacizumab as standard of care – I. Ray-Coquard
  • Maintenance olaparib plus bevacizumab (bev) after platinum-based chemotherapy plus bev in patients (pts) with newly diagnosed advanced high-grade ovarian cancer (HGOC): Efficacy by timing of surgery and residual tumor status in the Phase III PAOLA-1 trial – C. Grimm
  • Population adjusted indirect comparison of the SOLO1 and PAOLA-1/ENGOT-ov25 studies of olaparib with or without bevacizumab, bev alone and placebo in the maintenance treatment of women with newly diagnosed stage III/IV ovarian cancer with BRCA mutation – I. B. Vergote
  • Integration of veliparib (V) with front-line chemotherapy and maintenance in women with high-grade serous carcinoma of ovarian, fallopian tube, or primary peritoneal origin (HGSC) – R. Coleman
  • Anti-tumor activity of veliparib during combination phase with chemotherapy in VELIA study – D. O’Malley

View Abstracts

 Registration Link For OnDemand Webinar (SGO ConnectEd)

Webinar #3: Rare Tumors

Moderators/Distillants: Michael M. Frumovitz, MD, MPH, and Jubilee Brown, MD

  • MILO/ENGOT-ov11: Phase-3 Study of Binimetinib versus Physician’s Choice Chemotherapy in Recurrent or Persistent Low-grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum – R. N. Grisham
  • A Randomized Phase II/III Study to Assess the Efficacy of Trametinib in Patients with Recurrent or Progressive Low-Grade Serous Ovarian or Peritoneal Cancer – D. M. Gershenson
  • Phase II study of enzalutamide in androgen receptor positive (AR+) recurrent high-grade and low-grade serous ovarian cancer – R. N. Grisham
  • Phase II study of pembrolizumab for high-grade neuroendocrine tumors of the cervix and vulva – M. Frumovitz
  • Phase II study of durvalumab alone or in combination with ADXS11-001 (AXAL) in recurrent/persistent or metastatic cervical cancer – B. M. Slomovitz
  • A randomized phase II study of chemoradiation and pembrolizumab for locally advanced cervical cancer: Presentation of safety data – Linda Duska, MD

View Abstracts

 Registration Link For OnDemand Webinar (SGO ConnectEd)

Webinar #4: Molecular Testing and Patient Selection in Ovarian Cancer

Moderators/Distillants: Rebecca C. Arend, MD, MPH, and Charles N. Landen, MD

  • Safety of veliparib in combination with chemotherapy and as maintenance in front-line ovarian cancer: Results in BRCAm, hrd, and whole populations from the VELIA trial – C. Aghajanian
  • Exploring the relationship between homologous recombination score and progression-free survival in BRCA wildtype ovarian carcinoma: Analysis of veliparib plus carboplatin/paclitaxel in the velia study – E. Swisher
  • Randomized phase II CLIO study on olaparib monotherapy versus chemotherapy in platinum-sensitive recurrent ovarian cancer – L. Loverix
  • Postprogression outcomes in patients with ovarian carcinoma associated with a mutation in a non-BRCA homologous recombination repair gene receiving rucaparib maintenance treatment: Results from the phase III study ARIEL3 – D. M. O’Malley

View Abstracts

 Registration Link For OnDemand Webinar (SGO ConnectEd)

Webinar #5: Surgical Innovations in Gynecologic Cancers

Moderators/Distillants: Kara C. Long Roche, MD, and Jamie N. Bakkum-Gamez, MD

  • Validation of sentinel lymph biopsy in patients with early stage vulvar cancer: A prospective trial of 1552 women (GROINSS-V II/GOG270) – B. M. Slomovitz
  • Radiotherapy as an alternative treatment for inguinofemoral lymphadenectomy in vulvar cancer patients with a metastatic sentinel node: Results of GROINSS-V II – A. van Der Zee
  • Sentinel lymph node biopsy versus lymphadenectomy for high-grade endometrial cancer staging (SENTOR trial): A prospective multicenter cohort study – M. C. Cusimano
  • Characterization of patients with isolated tumor cells and micrometastasis on sentinel lymph node biopsy performed for endometrial cancer staging – K. A. Underkofler
  • Does the presence of nodal micrometastases or isolated tumor cells increase the risk of recurrent endometrioid adenocarcinoma? A case control study. – T. Castellano

View Abstracts

 Registration Link For OnDemand Webinar (SGO ConnectEd)

Webinar #6: Front Line Ovarian Cancer: Turning up the Heat on Immunotherapy

Moderators/Distillants: Leslie M. Randall, MD, and Dan S. Veljovich, MD

  • Avelumab2 in combination with and/or following chemotherapy vs chemotherapy alone in patients with previously untreated epithelial ovarian cancer: Results from the phase 3 javelin ovarian 100 trial – J. Ledermann
  • Randomized double-blind placebo controlled trial of primary maintenance vigil immunotherapy (VITAL study) in stage III/IV ovarian cancer: Efficacy assessment in BRCA1/2-wt patients – R. Rocconi
  • Phase II OVARIO study of niraparib + bevacizumab therapy in advanced ovarian cancer following front-line platinum-based chemotherapy with bevacizumab – M. Hardesty
  • A pilot study of nivolumab in combination with front-line neoadjuvant dose-dense paclitaxel and carboplatin chemotherapy in patients with high-grade serous ovarian cancer – C. F. Friedman

Moderators to synthesize these 4 abstracts with input from the authors:

  • Heated intraperitoneal chemotherapy (HIPEC) use for ovarian cancer in the United States increases after publication of clinical trial and is associated with higher short-term cost and morbidity
  • Comparison of outcomes with utilization of hyperthermic intraperitoneal chemotherapy with paclitaxel and cisplatin versus cisplatin alone at interval debulking surgery in women with epithelial ovarian cancer
  • Comparison of outcomes with utilization of hyperthermic intraperitoneal chemotherapy (HIPEC) at time of minimally invasive interval debulking surgery versus laparotomy
  • Hyperthermic intraperitoneal chemotherapy at the time of minimally invasive interval debulking surgery

View Abstracts

 Registration Link For OnDemand Webinar (SGO ConnectEd)

Webinar #7: Genetic Discoveries and Pathologic Variations in Ovarian Cancer

Moderators/Distillants: Charles N. Landen, MD, and Barbara S. Norquist, MD

  • Histopathological characterization of the tubal fimbria reveals a subgroup of BRCA1 mutation carriers with tumor-promoting gene-set enrichment – Y. Raz
  • Metabolomic and transcriptomic response to neoadjuvant chemotherapy in HGSOC – A. M. Davis
  • Compositional and architectural characterization of high-grade serous ovarian carcinomas using single cell technologies and multiplex microscopy – S. H. Kim
  • BRCA tumor-testing in a tertiary referral center: Are we missing something or not? – C. Marchetti
  • Comparing mutation frequencies for homologous recombination genes in uterine serous and high-grade serous ovarian carcinomas: A case for homologous recombination deficiency testing in uterine serous carcinoma – J. J. Wallbillich
  • Inherited mutations in fallopian tube, ovarian, and primary peritoneal carcinoma: Changes in diagnoses and mutational frequency over 20 years – A. S. Weiss

View Abstracts

 Registration Link For OnDemand Webinar (SGO ConnectEd)

Webinar #8: Developmental Therapeutics in Gynecologic Cancer

Moderators/Distillants: Kunle O. Odunsi, MD, PhD, and Debra L. Richardson, MD

  • A phase I/II study of chemo-immunotherapy with durvalumab (durva) and pegylated liposomal doxorubicin (PLD) in platinum-resistant recurrent ovarian cancer (PROC): Genomic sequencing and updated efficacy results – R. E. O’Cearbhaill
  • Pembrolizumab window study: Illuminating the immunologic landscape in gynecologic cancers – S. Gaillard
  • Intraperitoneal or subcutaneously administered IL-15 superagonist (N-803) increases NK cell cytotoxicity in ovarian cancer – M. Geller
  • A phase I clinical trial of autologous chimeric antigen receptor (CAR) T cells genetically engineered to secrete IL-12 and to target the MUC16ecto antigen in patients (pts) with MUC16ecto+ recurrent high-grade serous ovarian cancer (HGSOC) – R. E. O’Cearbhaill
  • A phase 1 study of XMT-1536 in patients with solid tumors likely to express NaPi2b: A summary of dose escalation – D. Richardson

Moderators to synthesize these 4 abstracts with input from the authors:

  • Demcizumab combined with paclitaxel for platinum-resistant ovarian, primary peritoneal, and fallopian tube cancer (EOC): The SIERRA multi-institutional open-label phase Ib trial
  • A phase Ib study of navicixizumab and weekly paclitaxel in heavily pretreated platinum resistant ovarian, primary peritoneal or fallopian tube cancer
  • A randomized phase II evaluation of weekly gemcitabine plus pazopanib versus weekly gemcitabine alone in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma
  • Apatinib plus camrelizumab in patients with advanced cervical cancer: A multicentre, open-label, single-arm, phase II trial

View Abstracts

 Registration Link For OnDemand Webinar (SGO ConnectEd)

Top